We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
Read MoreHide Full Article
Key Takeaways
OptimizeRx is set to post Q1 results on May 12, with revenues projected to fall 15.9% year over year.
OPRX cites weaker managed services demand and conservative pharma spending as key headwinds.
The company expects 2026 growth to be backloaded, with stronger performance in the second half.
OptimizeRx Corporation (OPRX - Free Report) will report its first-quarter 2026 results on May 12, after the market close.
The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at 1 cent, compared with 8 cents reported in the prior-year quarter. The estimate has deteriorated from 2 cents per share over the past 60 days.
Image Source: Zacks Investment Research
The consensus estimate for total revenues is pinned at $18.45 million, down 15.9% year over year.
OPRX’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 390.29%.
What Our Model Predicts for OPRX’s Q1
Our proven model does not predict an earnings beat for OPRX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
OPRX has an Earnings ESP of -500.00% and a Zacks Rank #3.
Management has flagged a slower start to 2026, caused by macro and industry-specific dynamics. Softness in contracted revenues, linked to a broader market shift away from managed services, is an overhang. Management noted that the first half of 2025 saw $9 million higher managed services revenues, which are not expected to repeat this time around.
Moreover, volatility is increasing as pharmaceutical clients adopt a more conservative spending approach amid Most Favored Nation (“MFN”) pricing dynamics.
Management has lowered the revenue outlook for 2026 to $109-$114 million compared with the $118-$124 million provided at the end of the third quarter of 2025. The year is expected to be backloaded, with first-half revenues at 40% and 60% expected for the second half. As a result, the first-quarter performance is expected to have reflected these headwinds.
Coming to margins, while gross margin was 74.8% in the fourth quarter of 2025, OptimizeRx has guided for moderation in 2026, with gross margins expected in the mid-60% range due to normalization in channel mix. The company reiterated its focus on adjusted EBITDA, guiding $21-$25 million for 2026. This is more than the previously mentioned $19-$22 million. In addition to a fixed cost base and scalable operating model, EBITDA is gaining from cost discipline measures (post the Medicx buyout).
Moreover, OptimizeRx emphasized that the pharma marketing spend headwinds appear temporary. Management noted that the company continues to see strong engagement across its network and is confident that the demand trends will cushion the business. It expects normalization over the coming quarters.
Additionally, the expanding adoption of OPRX’s Dynamic Audience Activation Platform (“DAAP”) bodes well. The DAAP platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences across a strong network of clinical and personal platforms.
The company has also been seeing momentum across both established pharmaceutical clients and mid-tier/long-tail life science customers.
On the last earnings call, OptimizeRx addressed AI concerns, positioning it as a tailwind rather than a disruption risk, highlighting that AI is expected to free up marketing budgets, which are usually allocated up to 50% to content creation. These could be reallocated toward marketing execution and audience reach, areas where OptimizeRx shines, as highlighted by management.
OPRX Stock Plunges
Shares of OptimizeRx have lost 60.8% in the past six months compared with the Zacks Computer Software industry’s decline of 19.1%.
GoodRx Holdings is another digital healthcare company focused on medication savings in the United States and used by nearly 25 million consumers. Doximity is a top-tier U.S. medical network, used by more than 85% of physicians and a majority of NPs and PAs. Phreesia offers an automated platform for healthcare organizations to manage patient intake.
Key Valuation Metric for OPRX
OPRX is trading at a forward 12-month price-to-sales ratio of 1.05, a discount compared with the Zacks Computer Software industry’s 7.05 and the Zacks Computer & Technology sector’s 6.78.
Image Source: Zacks Investment Research
In comparison, DOCS, GDRX and PHR are trading at multiples of 6.81X, 1.12X and 1.1X, respectively.
What to Do With OPRX Stock Before Q1
Reduced near-term visibility and management’s expectation of a backloaded year, OPRX appears vulnerable to near-term volatility. On the flip side, strong EBITDA guidance and long-term platform traction provide a strong underlying narrative.
Overall, existing investors could wait for commentary at the upcoming earnings call, while new investors would be better off waiting for a favorable entry point.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
Key Takeaways
OptimizeRx Corporation (OPRX - Free Report) will report its first-quarter 2026 results on May 12, after the market close.
The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at 1 cent, compared with 8 cents reported in the prior-year quarter. The estimate has deteriorated from 2 cents per share over the past 60 days.
Image Source: Zacks Investment Research
The consensus estimate for total revenues is pinned at $18.45 million, down 15.9% year over year.
OPRX’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 390.29%.
What Our Model Predicts for OPRX’s Q1
Our proven model does not predict an earnings beat for OPRX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
OPRX has an Earnings ESP of -500.00% and a Zacks Rank #3.
You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Factors to Focus on Ahead of OPRX’s Q1 Earnings
Management has flagged a slower start to 2026, caused by macro and industry-specific dynamics. Softness in contracted revenues, linked to a broader market shift away from managed services, is an overhang. Management noted that the first half of 2025 saw $9 million higher managed services revenues, which are not expected to repeat this time around.
Moreover, volatility is increasing as pharmaceutical clients adopt a more conservative spending approach amid Most Favored Nation (“MFN”) pricing dynamics.
Management has lowered the revenue outlook for 2026 to $109-$114 million compared with the $118-$124 million provided at the end of the third quarter of 2025. The year is expected to be backloaded, with first-half revenues at 40% and 60% expected for the second half. As a result, the first-quarter performance is expected to have reflected these headwinds.
Coming to margins, while gross margin was 74.8% in the fourth quarter of 2025, OptimizeRx has guided for moderation in 2026, with gross margins expected in the mid-60% range due to normalization in channel mix. The company reiterated its focus on adjusted EBITDA, guiding $21-$25 million for 2026. This is more than the previously mentioned $19-$22 million. In addition to a fixed cost base and scalable operating model, EBITDA is gaining from cost discipline measures (post the Medicx buyout).
Moreover, OptimizeRx emphasized that the pharma marketing spend headwinds appear temporary. Management noted that the company continues to see strong engagement across its network and is confident that the demand trends will cushion the business. It expects normalization over the coming quarters.
OptimizeRx Corp. Price and EPS Surprise
OptimizeRx Corp. price-eps-surprise | OptimizeRx Corp. Quote
Additionally, the expanding adoption of OPRX’s Dynamic Audience Activation Platform (“DAAP”) bodes well. The DAAP platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences across a strong network of clinical and personal platforms.
The company has also been seeing momentum across both established pharmaceutical clients and mid-tier/long-tail life science customers.
On the last earnings call, OptimizeRx addressed AI concerns, positioning it as a tailwind rather than a disruption risk, highlighting that AI is expected to free up marketing budgets, which are usually allocated up to 50% to content creation. These could be reallocated toward marketing execution and audience reach, areas where OptimizeRx shines, as highlighted by management.
OPRX Stock Plunges
Shares of OptimizeRx have lost 60.8% in the past six months compared with the Zacks Computer Software industry’s decline of 19.1%.
Price Performance
Image Source: Zacks Investment Research
Peers such as GoodRx Holdings, Inc. (GDRX - Free Report) , Phreesia (PHR - Free Report) and Doximity (DOCS - Free Report) have declined 16%, 57.9% and 51.1%, respectively.
GoodRx Holdings is another digital healthcare company focused on medication savings in the United States and used by nearly 25 million consumers. Doximity is a top-tier U.S. medical network, used by more than 85% of physicians and a majority of NPs and PAs. Phreesia offers an automated platform for healthcare organizations to manage patient intake.
Key Valuation Metric for OPRX
OPRX is trading at a forward 12-month price-to-sales ratio of 1.05, a discount compared with the Zacks Computer Software industry’s 7.05 and the Zacks Computer & Technology sector’s 6.78.
Image Source: Zacks Investment Research
In comparison, DOCS, GDRX and PHR are trading at multiples of 6.81X, 1.12X and 1.1X, respectively.
What to Do With OPRX Stock Before Q1
Reduced near-term visibility and management’s expectation of a backloaded year, OPRX appears vulnerable to near-term volatility. On the flip side, strong EBITDA guidance and long-term platform traction provide a strong underlying narrative.
Overall, existing investors could wait for commentary at the upcoming earnings call, while new investors would be better off waiting for a favorable entry point.